The Charles River Associates Life Sciences Policy team, MSD, and Economist Impact are hosting a virtual expert roundtable on 30 March, 2023. A terrific speaker lineup will share diverse perspectives on these themes, plus implications for innovation and health policy.
Overview
New drugs bring undeniable benefits: treating and curing disease, lengthening lives and improving their quality. That makes investment in research and development (R&D) a priority not only for biotech and pharma companies, but also for governments and public institutions. As the public and private sectors play to their strengths they are developing a better ability to collaborate. Meanwhile, sources of financing have blended across therapeutic areas and innovation models are shifting to promote R&D efficiency.
Across the world, life science clusters that unite science and commerce have showcased the synergies created when public and private players are co-located, from companies and universities to research centres and investors. But there remains a debate over whether public or private-sector funding is better at bringing innovative medicines to market. Where public money is involved in developing drugs that businesses end up selling, there can be a perception that the public is paying twice for new medicines. What are the arguments for and against that view? In Europe, how will stronger innovation ecosystems and more appropriate reimbursement agreements contribute to more new medications entering the market? How can the strengths of stakeholders in these ecosystems be harnessed, through the most appropriate financing structures, to bring new drugs to market and improve access to them?
Join “Collaboration for new therapies: maximising funding and innovation,” a webinar sponsored by Merck Sharp & Dohme (MSD) and programmed by Economist Impact.
Questions to be discussed include:
● How can stakeholders in life science ecosystems work together to advance innovation and optimise efficiency?
● What is the right balance between commercial incentives and affordability for new drugs? When should policymakers intervene in how they are funded and priced?
● What makes a successful biopharma ecosystem, and how can local strengths be put to better use outside well-known biopharma clusters
Click here to register.
